Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1158

1.

Loss of DIP2C in RKO cells stimulates changes in DNA methylation and epithelial-mesenchymal transition.

Larsson C, Ali MA, Pandzic T, Lindroth AM, He L, Sjöblom T.

BMC Cancer. 2017 Jul 17;17(1):487. doi: 10.1186/s12885-017-3472-5.

2.

The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome.

Caswell DR, Swanton C.

BMC Med. 2017 Jul 18;15(1):133. doi: 10.1186/s12916-017-0900-y. Review.

3.

Interpreting whole genome and exome sequencing data of individual gastric cancer samples.

Esser D, Holze N, Haag J, Schreiber S, Krüger S, Warneke V, Rosenstiel P, Röcken C.

BMC Genomics. 2017 Jul 6;18(1):517. doi: 10.1186/s12864-017-3895-z.

4.

DNA Mutations May Not Be the Cause of Cancer.

Adjiri A.

Oncol Ther. 2017;5(1):85-101. doi: 10.1007/s40487-017-0047-1. Epub 2017 May 15.

5.

Computational Methods for Characterizing Cancer Mutational Heterogeneity.

Vandin F.

Front Genet. 2017 Jun 14;8:83. doi: 10.3389/fgene.2017.00083. eCollection 2017. Review.

6.

Analysis of Isocitrate Dehydrogenase -2 (IDH-2) Activity in Human Serum as a Biomarker in Chemotherapy Patients of Breast Carcinoma: A Case-Control Study.

Gavel R, Mishra SP, Khanna S, Khanna R, Shah AG.

J Clin Diagn Res. 2017 May;11(5):BC05-BC08. doi: 10.7860/JCDR/2017/21886.9842. Epub 2017 May 1.

7.

SUN1 silencing inhibits cell growth through G0/G1 phase arrest in lung adenocarcinoma.

Huang W, Huang H, Wang L, Hu J, Song W.

Onco Targets Ther. 2017 Jun 2;10:2825-2833. doi: 10.2147/OTT.S79727. eCollection 2017.

8.

The NF1 somatic mutational landscape in sporadic human cancers.

Philpott C, Tovell H, Frayling IM, Cooper DN, Upadhyaya M.

Hum Genomics. 2017 Jun 21;11(1):13. doi: 10.1186/s40246-017-0109-3. Review.

9.

Crystal structure of tubulin tyrosine ligase-like 3 reveals essential architectural elements unique to tubulin monoglycylases.

Garnham CP, Yu I, Li Y, Roll-Mecak A.

Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):6545-6550. doi: 10.1073/pnas.1617286114. Epub 2017 Jun 2.

PMID:
28576883
10.

High Level of Plasma EGFL6 Is Associated with Clinicopathological Characteristics in Patients with Oral Squamous Cell Carcinoma.

Chuang CY, Chen MK, Hsieh MJ, Yeh CM, Lin CW, Yang WE, Yang SF, Chou YE.

Int J Med Sci. 2017 Apr 8;14(5):419-424. doi: 10.7150/ijms.18555. eCollection 2017.

11.

Oncodomains: A protein domain-centric framework for analyzing rare variants in tumor samples.

Peterson TA, Gauran IIM, Park J, Park D, Kann MG.

PLoS Comput Biol. 2017 Apr 20;13(4):e1005428. doi: 10.1371/journal.pcbi.1005428. eCollection 2017 Apr.

12.

Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma.

Wittig-Blaich S, Wittig R, Schmidt S, Lyer S, Bewerunge-Hudler M, Gronert-Sum S, Strobel-Freidekind O, Müller C, List M, Jaskot A, Christiansen H, Hafner M, Schadendorf D, Block I, Mollenhauer J.

Oncotarget. 2017 Apr 4;8(14):23760-23774. doi: 10.18632/oncotarget.15863.

13.

Comparison of different cell type correction methods for genome-scale epigenetics studies.

Kaushal A, Zhang H, Karmaus WJJ, Ray M, Torres MA, Smith AK, Wang SL.

BMC Bioinformatics. 2017 Apr 14;18(1):216. doi: 10.1186/s12859-017-1611-2.

14.

VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation.

Shathasivam P, Kollara A, Spybey T, Park S, Clarke B, Ringuette MJ, Brown TJ.

Br J Cancer. 2017 Apr 11;116(8):1065-1076. doi: 10.1038/bjc.2017.51. Epub 2017 Mar 16.

PMID:
28301874
15.

A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer.

Forés M, Simón-Carrasco L, Ajuria L, Samper N, González-Crespo S, Drosten M, Barbacid M, Jiménez G.

PLoS Genet. 2017 Mar 9;13(3):e1006622. doi: 10.1371/journal.pgen.1006622. eCollection 2017 Mar.

16.

Precision medicine driven by cancer systems biology.

Filipp FV.

Cancer Metastasis Rev. 2017 Mar;36(1):91-108. doi: 10.1007/s10555-017-9662-4.

17.

Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways.

Liao XH, Zhang AL, Zheng M, Li MQ, Chen CP, Xu H, Chu QS, Yang D, Lu W, Tsai TF, Liu H, Zhou XZ, Lu KP.

Sci Rep. 2017 Mar 6;7:43639. doi: 10.1038/srep43639.

18.

Identification of outcome-related driver mutations in cancer using conditional co-occurrence distributions.

Treviño V, Martínez-Ledesma E, Tamez-Peña J.

Sci Rep. 2017 Feb 27;7:43350. doi: 10.1038/srep43350.

19.

Molecular markers of paragangliomas/pheochromocytomas.

Zhikrivetskaya SO, Snezhkina AV, Zaretsky AR, Alekseev BY, Pokrovsky AV, Golovyuk AL, Melnikova NV, Stepanov OA, Kalinin DV, Moskalev AA, Krasnov GS, Dmitriev AA, Kudryavtseva AV.

Oncotarget. 2017 Apr 11;8(15):25756-25782. doi: 10.18632/oncotarget.15201. Review.

20.

Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer.

Andretta E, Cartón-García F, Martínez-Barriocanal Á, de Marcondes PG, Jimenez-Flores LM, Macaya I, Bazzocco S, Bilic J, Rodrigues P, Nieto R, Landolfi S, Ramon Y Cajal S, Schwartz S, Brown A, Dopeso H, Arango D.

Sci Rep. 2017 Feb 7;7:41576. doi: 10.1038/srep41576.

Supplemental Content

Support Center